The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2012-01-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-11-0750PMID 22228822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.

  2010cited by this paper
• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

  2010cited by this paper
• Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

  2010cited by this paper
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.

  2009cited by this paper
• PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

  2009cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008influential reference
• The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

  2008cited by this paper
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

  2007cited by this paper
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.

  2007cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007influential reference
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer

  2005cited by this paper
• EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

  2004cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002influential reference
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper

• Synthesis and anti-lung cancer evaluation of fused pyrazolo[3,4-b]pyridine linked isoxazoles and 1,2,3-triazoles: PEG-400 mediated one-pot reaction under microwave irradiation.

  2026cites this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).

  2026cites this paper
• Synthesis and antitumor activity of a novel class of covalent inhibitors of EGFR with 2-indolone backbone.

  2025cites this paper
• A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR/STAT3 signaling pathway.

  2025cites this paper
• Identification of novel inhibitors targeting EGFR L858R/T790M/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches.

  2025cites this paper
• Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs

  2025cites this paper
• Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.

  2025cites this paper
• Impact of trifluoromethyl Ugi adducts as anticancer agents: EGFR inhibition, apoptosis induction and miRNA up-regulation

  2025cites this paper
• Mechanistic insights into the allosteric inhibition of EGFR by dibenzodiazepinone DDC4002: A molecular dynamics, binding free energy, conformational motions and thermodynamic landscape approach

  2025cites this paper
• Synthesis of Pyrido[2,3-d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor-Targeted Molecular Docking Toward Novel Anticancer Leads.

  2025cites this paper
• Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies

  2024cites this paper
• From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer.

  2024cites this paper
• EGFR-Targeted Therapies: A Literature Review

  2024cites this paper
• Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.

  2024cites this paper
• Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study

  2024cites this paper
• Pyrrolo[2,3-d]pyrimidines as EGFR and VEGFR kinase inhibitors: a comprehensive SAR review.

  2023cites this paper
• 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight.

  2023cites this paper
• Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.

  2023cites this paper
• Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket

  2023cites this paper
• Design and synthesis of novel pyrazolopyrimidine candidates as promising EGFR-T790M inhibitors and apoptosis inducers.

  2023cites this paper
• Discovery of new VEGFR-2 inhibitors and apoptosis inducer-based thieno[2,3-d]pyrimidine.

  2023cites this paper
• Structural identification of novel pyrimidine derivatives as epidermal growth factor receptor inhibitors using 3D QSAR, molecular docking, and MMGBSA analysis: a rational approach in anticancer drug design

  2023cites this paper
• Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.

  2023cites this paper
• Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors

  2023cites this paper
• Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation

  2022cites this paper
• Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.

  2022cites this paper
• 三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识（2022年版）

  2022cites this paper
• Discovery of EMD37, a 1,2,4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity.

  2022cites this paper
• Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFRT790M/L858R inhibitors to treat non-small cell lung cancer.

  2022cites this paper
• New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies

  2022cites this paper
• Design, synthesis and biological evaluation of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds as EGFR-TKIs.

  2022cites this paper
• Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations

  2022cites this paper
• Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M

  2022cites this paper
• Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers

  2022cites this paper
• Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors

  2022cites this paper
• Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes

  2022cites this paper
• A sensitive and selective SNV detection strategy based on non-canonical dsDNA structure preference of endonuclease IV

  2022cites this paper
• Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation

  2022cites this paper
• Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab

  2022cites this paper
• Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.

  2021cites this paper
• Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant.

  2021cites this paper
• Computational identification of 2,4-disubstituted amino-pyrimidines as L858R/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulation

  2021cites this paper
• Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.

  2021cites this paper
• Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor

  2021cites this paper
• Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

  2021cites this paper
• Design and Synthesis of the Novel, Selective WZ4002 analogue as EGFR-L858R/T790M Tyrosine Kinase Inhibitors for Targeted Drug Therapy in Non-Small-Cell Lung Cancer (NSCLC)

  2021cites this paper
• Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

  2021cites this paper
• Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma

  2021cites this paper
• Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer

  2021cites this paper
• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy

  2021cites this paper
• Enhanced Efficacy of Gefitinib in Drug‐Sensitive and Drug‐Resistant Cancer Cell Lines after Arming with a Singlet Oxygen Releasing Moiety

  2020cites this paper
• OTT_A_279540 13425..13435

  2020cites this paper
• Targeting molecular subtypes in solid cancers: successes and failures.

  2020cites this paper
• Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice.

  2020cites this paper
• The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.

  2020cites this paper
• Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M.

  2020cites this paper
• Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827.

  2020cites this paper
• Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

  2020cites this paper
• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.

  2020cites this paper
• Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

  2019cites this paper
• mPRα mediates P4/Org OD02‐0 to improve the sensitivity of lung adenocarcinoma to EGFR‐TKIs via the EGFR‐SRC‐ERK1/2 pathway

  2019cites this paper
• First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

  2019cites this paper
• Cell signaling and cancer: a mechanistic insight into drug resistance

  2019cites this paper
• a selective mutant EGFR inhibitor, shows activity against tumors expressing various EGFR mutations including T790M and uncommon mutations

  2019cites this paper
• Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

  2019cites this paper
• TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X

  2019cites this paper
• Progress in Research on Tumor Metastasis Inhibitors.

  2019cites this paper
• Current Approaches in the Development of Covalent Reversible EGFR Inhibitors

  2019cites this paper
• Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non‐small‐cell lung carcinoma harbouring EGFR T790M mutations

  2019influential citation
• Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.

  2018cites this paper
• Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

  2018cites this paper
• Advances in studies of tyrosine kinase inhibitors and their acquired resistance

  2018cites this paper
• Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers.

  2018cites this paper
• Developing Design Guidelines for Precision Oncology Reports

  2018cites this paper
• Mechanisms of acquired resistance to afatinib clarified with liquid biopsy

  2018cites this paper
• Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment

  2018cites this paper
• New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.

  2018cites this paper
• Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs.

  2018cites this paper
• Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report

  2018cites this paper
• Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors

  2018cites this paper
• TMB-Intermediate ( 11 Muts / Mb ) Tumor Mutational Burden

  2018cites this paper
• The Discovery of Osimertinib (TAGRISSO™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non‐Small Cell Lung Cancer

  2018cites this paper
• Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.

  2018cites this paper
• Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.

  2018cites this paper
• Resistance mechanisms in lung cancer patients with EGFR or ALK aberrations treated with kinase inhibitors

  2017cites this paper
• University of Groningen Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer , a review of the literature

  2017cites this paper
• Mechanism of action of Tarloxotinib, a hypoxia-activated pan-HER inhibitor: Potential for targeting wild-type EGFR in non-small cell lung cancer

  2017cites this paper
• YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells

  2017cites this paper
• Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.

  2017cites this paper
• Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.

  2017cites this paper
• Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.

  2017cites this paper
• Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR

  2017cites this paper
• Role of epidermal growth factor receptor in lung cancer and targeted therapies.

  2017cites this paper
• Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?

  2017cites this paper
• Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

  2017cites this paper
• MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia

  2017cites this paper
• Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

  2017cites this paper
• Hot Topics in Pneumologia Interventistica

  2017cites this paper
• Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

  2017cites this paper